ABSTRACT Severe mortality due to the COVID-19 pandemic resulted from the lack of effective treatment. Although COVID-19 vaccines are available, their side effects have become a challenge for clinical use in patients with chronic diseases, especially cancer patients. In the current report, we applied network pharmacology and systematic bioinformatics to explore the use of biochanin A in patients with colorectal cancer (CRC) and COVID-19 infection. Using the network pharmacology approach, we identified two clusters of genes involved in immune response ( IL1A, IL2 , and IL6R ) and cell proliferation ( CCND1, PPARG , and EGFR ) mediated by biochanin A in CRC/COVID-19 condition. The functional analysis of these two gene clusters further illustrated the effects of biochanin A on interleukin-6 production and cytokine-cytokine receptor interaction in CRC/COVID-19 pathology. In addition, pathway analysis demonstrated the control of PI3K-Akt and JAK-STAT signaling pathways by biochanin A in the treatment of CRC/COVID-19. The findings of this study provide a therapeutic option for combination therapy against COVID-19 infection in CRC patients.
【저자키워드】 COVID-19, bioinformatics, Colorectal cancer, biochanin a, biological function, pharmaceutical target, 【초록키워드】 Treatment, pathology, COVID-19 vaccine, immune response, Mortality, COVID-19 pandemic, interleukin-6, network pharmacology, combination therapy, Pathway analysis, COVID-19 infection, Patient, Cancer patients, Cluster, receptor, EGFR, patients, Interaction, Analysis, JAK-STAT signaling pathway, cell proliferation, therapeutic option, Chronic diseases, Clinical use, Side effect, IL6R, PPARG, CCND1, IL1A, gene cluster, Effect, approach, effective, lack, involved, addition, applied, functional, demonstrated, IL2, 【제목키워드】 in-silico, pharmacological target, feature,